Immunotherapy and chemotherapy before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new immunotherapy drug (pucotenlimab) combined with chemotherapy before surgery for head and neck cancer. The goal is to see if this combination shrinks the tumor and improves outcomes for patients with locally advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your cancer must be a type of head and neck squamous cell carcinoma – meaning it started in the mouth, throat (oropharynx), voice box (larynx), or lower throat (hypopharynx) – and be at stage III or IVA.
- You must not have had any treatment for this cancer before joining the study.
- You must be strong enough to undergo standard surgery after the study treatment, and your overall health status should be good (ECOG score 0 or 1).
- You must not have an active autoimmune disease (like lupus or rheumatoid arthritis that requires treatment), and you must not have another active cancer.
- You must have adequate organ function, as shown by blood tests (for example, kidney, liver, and blood cell counts within normal limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called pabliximab (an immunotherapy) given before surgery to shrink head and neck tumors. It aims to make surgery more effective and may improve outcomes for people with this cancer.
This trial tests a combination of drugs before surgery for head and neck cancer. It aims to shrink tumors and improve outcomes, and the study compares adding another targeted drug to the standard combination.
This trial tests two different drug combos—one using an EGFR-targeted therapy alone, the other adding an immunotherapy—before standard chemoradiation for locally advanced head and neck cancer. The goal is to see which approach works better without prior treatment.
This trial is testing a new combination of drugs given before surgery (neoadjuvant) and followed by radiation after surgery to treat locally advanced head and neck cancer. The goal is to see if this approach is safe and effective, and may improve outcomes for patients who have not yet been treated.
This trial is testing a combination of two drugs (becotatug vedotin and pucotenlimab) given before surgery to shrink recurrent head and neck cancer that has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this approach helps make the tumor removable and improves outcomes.
This trial tests a new combination of two drugs (one targeted therapy and one immunotherapy) plus standard chemotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Squamous Cell Carcinoma of Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.